Native valve and late prosthetic valve (>1 year), community acquired endocarditis, subacute course |
Ampicillin-sulbactam + |
12 g/day** i.v. in 4-6 doses |
4 |
6 |
Gentamicin should be avoided in patients with initial high serum level of creatinine |
Gentamicin |
3 mg/kg/day i.v. in 1 dose |
2 |
2 |
|
Native valve and late prosthetic valve (>1 year), community acquired endocarditis, acute course |
Vancomycin + |
30-60 mg/kg/day i.v. in 2-3 doses |
4-6 |
≥6 |
Duration of treatment should be 6 and ≥6 weeks for native and prosthetic valve endocarditis, respectively, especially in the case of complicated IE, such as with metastatic foci, etc. |
Ampicillin- sulbactam, or |
12 g/day** i.v. in 4-6 doses |
4-6 |
≥6 |
Ceftriaxone |
2 gr/day, i.v. in 1 dose |
4-6 |
≥6 |
Native valve and late prosthetic valve (>1 year), healthcare associated endocarditis |
Vancomycin + |
30-60 mg/kg/day i.v. in 2-3 doses |
4 |
6 |
|
Cefepime |
6 gr/day, i.v. in 3 doses |
4 |
6 |
|
Native valve and late prosthetic valve (>1 year) endocarditis, b-lactam allergy |
Vancomycin + |
30-60 mg/kg/day i.v. in 2-3 doses |
4 |
6 |
Gentamicin should be avoided in patients with a higher risk of nephrotoxicity |
Gentamicin |
3 mg/kg/day i.v. in 1 dose |
2 |
2 |
|
Early prosthetic valve endocarditis (≤1 year) |
Vancomycin + |
30-60 mg/kg/day i.v. in 2-3 doses |
|
6 |
|
Gentamicin + |
3 mg/kg/day i.v. in 1 dose |
2 |
|
|
Cefepime + |
6 gr/day, i.v. in 3 doses |
6 |
|
|
Rifampin |
900 mg/day, i.v. or orally in 3 doses |
6 |
|
|
Cardiac Implantable Electronic Device (CIED) related lead or valve endocarditis |
Vancomycin ± |
30-60 mg/kg/day i.v. in 2-3 doses |
Antimicrobial therapy should be continued for 2-4 and 4-6 weeks for the lead and valve endocarditis, respectively, after the removal of the device. |
Addition of either gentamicin, or cefepime, or meropenem to vancomycin should be considered especially for septic patients with unstable hemodynamic status. |
Gentamicin, or |
3 mg/kg/day i.v. in 1 dose |
|
|
|
Cefepime, or |
6 gr/day, i.v. in 3 doses |
|
|
|
Meropenem |
3 gr/day, i.v. in 3 doses |
|
|
|
* Same regimens could be used for patients with negative blood cultures and serological test results. |